News | June 16, 2009

Bayer Completes Phase II Study on Alzheimer's Disease Tracer

June 12, 2009 – Bayer Schering Pharma AG, Germany, has completed its first global Phase II study analyzing the sensitivity and specificity of BAY 94-9172 (AV1/ZK) using positron emission tomography (PET) in patients with probable Alzheimer's disease compared to healthy volunteers. Information on BAY 94-9172 and related research and development programs will be presented during the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 - 17, 2009.

BAY 94-9172, currently in clinical development, is a 18F-labeled PET tracer and binds to beta amyloid, a protein that accumulates in the brain and that is considered being a pathological hallmark of Alzheimer's disease. Imaging with 18F-BAY 94-9172 should offer the possibility to support an early detection of Alzheimer's disease with an in-vivo imaging method.

"Beta amyloid has been proven to be a pathological hallmark of Alzheimer's disease and it is accumulated in the brain very early in the course of the disease. Currently, the detection of this protein and, thus, the definitive diagnosis of Alzheimer's disease is only possible upon post-mortem," said Thomas Balzer, M.D., head of Global Clinical Development Therapeutic Area Diagnostic Imaging. "Thus an in-vivo imaging method would be clinically very useful as it could help in the differentiation between different dementia forms and either exclude Alzheimer's disease or make it very likely. There is a high unmet medical need for a better and earlier differentiation between the various dementia forms and especially of Alzheimer's disease. We hope that BAY 94-9172 can contribute to this for the patient's benefit because an earlier and more accurate diagnosis allows for optimized care and treatment options," he added.

Bayer Schering Pharma has extended its Phase II program to further expand the number of imaged individuals and will also begin its pivotal Phase III global clinical development program of BAY 94-9172 in the second half of this year.

Related contributions at the Society of Nuclear Medicine (SNM) meeting in Toronto on June 13 - 17, 2009, include the following:

Test-retest variability of [18F]BAY94-9172 PET in Alzheimer's disease and normal ageing.
- Authors: Rowe, C.C.; Pejovska, S.; Mulligan, R.S.; Chan, G.; Jones, G.; Fels, L.; Kusi, H.; Reininger, C.; Rhode, B.; Putz, B.; O'Keefe, G.; Masters, C.L.; Villemagne, V.L.
Austin Hospital, Melbourne, VIC, Australia; Bayer Schering Pharma AG,
Berlin, Germany; The Mental Health Research Institute of Victoria, Melbourne, VIC, Australia.

- Scientific poster presentation at Neurology Posters, Poster Session I:
Multimodality and Non-Radioactive Molecular Imaging, Educational Exhibits, Cardiovascular & Neuroscience Track Posters.
Monday, June 15, 2:30 PM - 3:15 PM, Exhibit Hall E/F

Kinetic modeling of BAY94-9172 binding to beta-amyloid in human brains using PET data.
- Authors: Becker, G.; Barthel, H.; Luthardt, J.; Patt, M.; Hammerstein, E.; Eggers, B.; Reininger, C.; Rohde, B.; Hegerl, U.; Gertz, H.-J.; Sabri, O. Departments of Nuclear Medicine and Psychiatry, University of Leipzig, Arzneimittelforschung Leipzig Ltd., Bayer Schering Pharma AG, Berlin, Germany

- Oral presentation at Dementia II Session: Tracer Properties, Evaluation
Tuesday, June 16, 12:30 - 2 PM, Room 701A

Quantification of the radiation risk caused by [F18]BAY94-9172, a new PET tracer for detection of cerebral beta-amyloid plaques.
- Authors: Sattler, B.; Seese, A.; Barthel, H.; Patt, M.; Schildan, A.; Zollmann, F.; Reininger, C.; Rohde, B.; Eggers, B.; Gertz, H.-J.; Hegerl, U.; Sabri, O. University Hospital Leipzig, Dept. of Nuclear medicine; Bayer Schering Pharma AG, Berlin; University Hospital Leipzig, Dept. of Psychiatry; Pharmaceutical Research Leipzig GmbH

- Scientific poster presentation at Dosimetry/ISRTRD Posters.
Poster session IV: Radiopharmaceutical Chemistry Track Posters.
Tuesday, June 16 , 5:15 - 6:00 PM, Exhibit Hall E/F

Comparisons of Animal-Human Translated and Human 18F-BAY94-9172 Amyloid Radiation Dosimetry.
- Authors: O'Keefe, G.J.; Saunder, T.H.; Gong, S.; Pathmaraj, K.U.; Tochon-Danguy, H.T.; Villemagne, V.; Dyrks, T.; Dinkelborg, L.; Holl, G.; Rowe, C.C. Centre for PET, Austin Hospital, Heidelberg, Australia; Bayer Schering Pharma AG, Berlin, Germany
- Scientific poster presentation at Dosimetry/ISRTRD Posters: Posters Session IV: Radiopharmaceutical Chemistry Track Posters.
Tuesday, June 16, 5:15 - 6:00 PM, Exhibit Hall E/F

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init